Clinical Trial

Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

Study acronym: BioMol-MA
Recruiting
View on ClinicalTrials.gov →
Summary
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-09.
Trial Details
NCT Number NCT06413459
Lead Sponsor Ospedale San Raffaele
Collaborators: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis Lung
Enrollment 40 participants
Start Date 2021-04-08
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-03-30 (estimated)
Updated on ClinicalTrials.gov 2024-05-16